Key Dates

Related Announcements

• September 28, 2023 - Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional).  See NOFO RFA-DA-25-047 
• September 28, 2023 - Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional).  See NOFO RFA-DA-25-048 

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants of change in the award budget language in the following notices of funding opportunities (NOFOs):

• RFA-DA-25-047 "Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)"
• RFA-DA-25-048 “Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)"

Part 2. Full Text of Announcement

Section II. Award Information

Award Budget

Currently, reads:

Budgets up to $306,872 total costs per year for Phase I and up to $2,045,816 total costs per year for Phase II may be requested. Please refer to current Omnibus hard cap levels for FY25 and FY26 applications. These limits are subject to change each year. 

Revised to read (in Bold italic):

Budgets up to $306,872 total costs for Phase I and up to $2,045,816 total costs for Phase II may be requested. Please refer to current Omnibus hard cap levels for FY25 and FY26 applications. These limits are subject to change each year. 

All other aspects of this NOFO remain the same.

Inquiries

Please direct all inquiries to:

Morris Flood, DHSc
National Institute on Drug Abuse (NIDA)
Phone: 301-496-6144
Email: morris.flood@nih.gov